Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans.
Bhattacharya C, Sandinge AS, Bragg RA, Heijer M, Yan J, Andersson LC, Jurva U, Pelay-Gimeno M, Vaes WHJ, de Ligt RAF, Gränfors M, Amilon C, Lindstedt EL, Menakuru SR, Garkaviy P, Weidolf L, Gopaul VS. Bhattacharya C, et al. Among authors: lindstedt el. Drug Metab Dispos. 2023 Apr;51(4):451-463. doi: 10.1124/dmd.122.001100. Epub 2023 Jan 13. Drug Metab Dispos. 2023. PMID: 36639243
Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5-Lipoxygenase Activating Protein Inhibitor.
Ericsson H, Nelander K, Lagerstrom-Fermer M, Balendran C, Bhat M, Chialda L, Gan LM, Heijer M, Kjaer M, Lambert J, Lindstedt EL, Forsberg GB, Whatling C, Skrtic S. Ericsson H, et al. Among authors: lindstedt el. Clin Transl Sci. 2018 May;11(3):330-338. doi: 10.1111/cts.12546. Epub 2018 Mar 8. Clin Transl Sci. 2018. PMID: 29517132 Free PMC article. Clinical Trial.
Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers.
Gan LM, Lagerström-Fermér M, Ericsson H, Nelander K, Lindstedt EL, Michaëlsson E, Kjaer M, Heijer M, Whatling C, Fuhr R. Gan LM, et al. Among authors: lindstedt el. Br J Clin Pharmacol. 2019 Apr;85(4):762-770. doi: 10.1111/bcp.13855. Epub 2019 Feb 18. Br J Clin Pharmacol. 2019. PMID: 30618054 Free PMC article. Clinical Trial.
Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability.
Ericsson H, Nelander K, Heijer M, Kjaer M, Lindstedt EL, Albayaty M, Forte P, Lagerström-Fermér M, Skrtic S. Ericsson H, et al. Among authors: lindstedt el. Clin Pharmacol Drug Dev. 2020 Apr;9(3):411-421. doi: 10.1002/cpdd.756. Epub 2019 Dec 2. Clin Pharmacol Drug Dev. 2020. PMID: 31793171 Free PMC article. Clinical Trial.
Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction.
Nelander K, Lagerstrom-Fermer M, Amilon C, Michaëlsson E, Heijer M, Kjaer M, Russell M, Han D, Lindstedt EL, Whatling C, Gan LM, Ericsson H. Nelander K, et al. Among authors: lindstedt el. Clin Transl Sci. 2021 May;14(3):812-819. doi: 10.1111/cts.12859. Epub 2021 May 2. Clin Transl Sci. 2021. PMID: 32770730 Free PMC article. Clinical Trial.
Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects.
Knöchel J, Nelander K, Heijer M, Lindstedt EL, Forsberg GB, Whatling C, Shimada H, Han DS, Gabrielsen A, Garkaviy P, Ericsson H. Knöchel J, et al. Among authors: lindstedt el. Clin Drug Investig. 2021 Oct;41(10):895-905. doi: 10.1007/s40261-021-01078-7. Epub 2021 Sep 21. Clin Drug Investig. 2021. PMID: 34546534 Free PMC article. Clinical Trial.
Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study.
Prescott E, Angerås O, Erlinge D, Grove EL, Hedman M, Jensen LO, Pernow J, Saraste A, Åkerblom A, Svedlund S, Rudvik A, Knöchel J, Lindstedt EL, Garkaviy P, Gan LM, Gabrielsen A. Prescott E, et al. Among authors: lindstedt el. Int J Cardiol. 2022 Oct 15;365:34-40. doi: 10.1016/j.ijcard.2022.07.016. Epub 2022 Jul 14. Int J Cardiol. 2022. PMID: 35842004 Free article. Clinical Trial.
Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction.
Inghardt T, Antonsson T, Ericsson C, Hovdal D, Johannesson P, Johansson C, Jurva U, Kajanus J, Kull B, Michaëlsson E, Pettersen A, Sjögren T, Sörensen H, Westerlund K, Lindstedt EL. Inghardt T, et al. Among authors: lindstedt el. J Med Chem. 2022 Sep 8;65(17):11485-11496. doi: 10.1021/acs.jmedchem.1c02141. Epub 2022 Aug 25. J Med Chem. 2022. PMID: 36005476 Free PMC article.
Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results.
Lam CSP, Lund LH, Shah SJ, Voors AA, Erlinge D, Saraste A, Pirazzi C, Grove EL, Barasa A, Schou M, Aziz A, Svedlund S, Wijngaarden JV, Lindstedt EL, Gustavsson A, Nelander K, Garkaviy P, Gan LM, Gabrielsen A. Lam CSP, et al. Among authors: lindstedt el. J Card Fail. 2024 Jan;30(1):104-110. doi: 10.1016/j.cardfail.2023.04.003. Epub 2023 Apr 16. J Card Fail. 2024. PMID: 37072105 Free article. Clinical Trial.
Correction to "Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction".
Inghardt T, Antonsson T, Ericsson C, Hovdal D, Johannesson P, Johansson C, Jurva U, Kajanus J, Kull B, Michaëlsson E, Pettersen A, Sjögren T, Sörensen H, Westerlund K, Lindstedt EL. Inghardt T, et al. Among authors: lindstedt el. J Med Chem. 2022 Oct 13;65(19):13482. doi: 10.1021/acs.jmedchem.2c01533. Epub 2022 Oct 3. J Med Chem. 2022. PMID: 36190771 Free PMC article. No abstract available.
20 results